India's image as the 'Pharmacy of the World' depends on the robustness of its domestic quality regulation. Discuss the reforms needed.

India supplies affordable generics worldwide, but that trust rests on the same regulator that protects Indian patients. In November 2026 the Health Ministry published a draft amendment to the Drugs Rules, 1945. It would suspend a manufacturer's licence immediately if its drug fails critical quality parameters [1]. The draft shows that quality reform is now urgent.

Why domestic quality shapes India's global image

• WHO estimates that at least 1 in 10 medicines in low- and middle-income countries are substandard or falsified. These products cost about US$ 30.5 billion a year [2]. Buyers in these markets judge a supplier by its weakest batch.
• One regulatory system certifies both domestic and export supply. A lapse at home therefore becomes a reputational risk abroad.

Gaps in the present system

• Procedural lag: a show-cause notice must come before suspension, so a drug already declared NSQ stays in circulation [1].
• Slow testing: a CAG audit in Haryana found that 7,947 of 7,975 NSQ cases had reached hospitals before the lab reports arrived [4].
• Weak labs: a parliamentary committee flagged shortages of instruments, trained analysts and validated test methods [6].
• Fragmented enforcement: action depends on coordination between CDSCO and State Drugs Controllers [5].

Reforms needed

• Legal: the final rule should notify a list of critical parameters and set a time limit for re-testing and appeal. A hearing after the action, accepted in Maneka Gandhi v. Union of India (1978), balances Article 21 with natural justice.
• Recall: every suspension should come with a mandatory batch recall, because suspension only stops new production.
• Manufacturing: enforce the revised Schedule M (GMP), notified through G.S.R. 922(E), 2023 [3], and give MSMEs support to comply.
• Inspection: scale up risk-based inspections. Inspections of 400 premises led to more than 300 regulatory actions [5].
• Capacity: fund State drug-testing labs and fill inspector vacancies. State supply corporations should test drugs before dispatch [4].
• Global: report NSQ alerts to WHO's Global Surveillance and Monitoring System [2], so that importing regulators learn of them quickly.

Strong domestic regulation is the foundation of India's pharmaceutical diplomacy. A system that tests fast, acts fast and stays fair, backed by capable States, will protect patients at home and keep trust abroad. It would advance SDG 3.8's goal of safe, quality-assured medicines and truly earn the 'Pharmacy of the World' title.